The Conformis (NASDAQ:CFMS) Share Price Is Up 139% And Shareholders Are Boasting About It

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right stock, you can make a lot more than 100%. For example, the Conformis, Inc. (NASDAQ:CFMS) share price has soared 139% return in just a single year. Better yet, the share price has gained 263% in the last quarter. The company reported its financial results recently; you can catch up on the latest numbers by reading our company report. In contrast, the longer term returns are negative, since the share price is 47% lower than it was three years ago.

See our latest analysis for Conformis

Given that Conformis didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Conformis grew its revenue by 17% last year. We respect that sort of growth, no doubt. While that revenue growth is pretty good the share price performance outshone it, with a lift of 139% as mentioned above. If the profitability is on the horizon then now could be a very exciting time to be a shareholder. Of course, we are always cautious about succumbing to 'fear of missing out' when a stock has shot up strongly.

You can see how revenue and earnings have changed over time in the image below, (click on the chart to see cashflow).

NasdaqGS:CFMS Income Statement, May 14th 2019
NasdaqGS:CFMS Income Statement, May 14th 2019

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

Advertisement

A Different Perspective

It's nice to see that Conformis shareholders have gained 139% (in total) over the last year. What is absolutely clear is that is far preferable to the dismal 19% average annual loss suffered over the last three years. We're generally cautious about putting too much weigh on shorter term data, but the recent improvement is definitely a positive. If you would like to research Conformis in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About NasdaqCM:CFMS

Conformis

Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation.

Fair value with mediocre balance sheet.

Advertisement

Weekly Picks

CE
Ceazar
SPAI logo
Ceazar on Sparc AI ·

When GPS fails: this small cap is fixing a $54B drone problem

Fair Value:CA$5.2540.0% undervalued
74 users have followed this narrative
0 users have commented on this narrative
18 users have liked this narrative
HE
HedgeY
IONQ logo
HedgeY on IonQ ·

The Best-Funded Quantum Platform and Still a Stock Priced for Perfection

Fair Value:US$482.3% overvalued
30 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
BL
BlackGoat
CBRS logo
BlackGoat on Cerebras Systems ·

The Wafer Giant Threatening NVIDIA's GPU Hegemony

Fair Value:US$415.5450.7% undervalued
52 users have followed this narrative
1 users have commented on this narrative
7 users have liked this narrative
IV
NFLX logo
Ivoed on Netflix ·

Netflix’s Business Quality Is Clear. The Harder Question Is Whether The Stock Is Still Cheap

Fair Value:US$825.3% undervalued
27 users have followed this narrative
2 users have commented on this narrative
8 users have liked this narrative

Updated Narratives

DR
DrPotato
TMV logo
DrPotato on TeamViewer ·

TeamViewer Set to Evolve from Stagnation to Enterprise Growth by 2028

Fair Value:€13.3260.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
JO
John_Eric
VEEV logo
John_Eric on Veeva Systems ·

AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability

Fair Value:US$32039.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
EU
European_Hidden_Gem_Stocks
CRI logo
European_Hidden_Gem_Stocks on Creotech Instruments ·

$CRI Creotech Instruments (WSE:CRI): Two Minute Drill

Fair Value:zł822.191.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75028.1% undervalued
80 users have followed this narrative
1 users have commented on this narrative
9 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$319.9631.3% undervalued
63 users have followed this narrative
9 users have commented on this narrative
19 users have liked this narrative
NI
niteco
AVGO logo
niteco on Broadcom ·

A Capital Allocation Favorite with Structural Importance

Fair Value:US$651.0544.6% undervalued
55 users have followed this narrative
0 users have commented on this narrative
12 users have liked this narrative